OQS
KLRS

Occudo Quantitative Strategies’s Kalaris Therapeutics KLRS Stock Holding History

Occudo Quantitative Strategies’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-532
Closed -$48K – 1454
2022
Q2 		$48K Buy
+532
New +$55.8K ﹤0.01% 1073

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Occudo Quantitative Strategies's KLRS Position: Q3 2022 in Review

Occudo Quantitative Strategies sold out of Kalaris Therapeutics (KLRS) in Q3 2022, closing a stake of 532 shares — an estimated $48K sold.

Occudo Quantitative Strategies first reported a position in KLRS in Q2 2022 and held it in 1 quarter. The position peaked at $48K in Q2 2022. 85 funds tracked by Wall St. Rank hold KLRS as of Q3 2022.

  • Occudo Quantitative Strategies reported no remaining Kalaris Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 532 Kalaris Therapeutics shares in Q3 2022, an estimated $48K.
  • Occudo Quantitative Strategies first reported a position in Kalaris Therapeutics in Q2 2022 and held it in 1 quarter.
  • Occudo Quantitative Strategies's Kalaris Therapeutics position peaked at $48K in Q2 2022.
  • 85 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q3 2022, filed 14 Nov 2022.